Alnylam Pharmaceuticals (ALNY) Other Gross PP&E Adjustments (2011 - 2026)

Alnylam Pharmaceuticals' Other Gross PP&E Adjustments history runs 16 years deep, the most recent figure standing at -$189.3 million for Q1 2026.

• Quarterly Other Gross PP&E Adjustments rose 4.02% year-over-year to -$189.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$189.3 million (up 4.02% YoY) and the FY2025 annual result came in at $640.9 million, up 10.13% from the prior year.
• Other Gross PP&E Adjustments was -$189.3 million for Q1 2026 at Alnylam Pharmaceuticals, down from $640.9 million in the prior quarter.
• Across five years, Other Gross PP&E Adjustments topped out at $640.9 million in Q4 2025 and bottomed at -$228.8 million in Q1 2022.
• A 5-year average of -$23.8 million and a median of -$196.4 million in 2024 frame the typical range for Other Gross PP&E Adjustments.
• Annual changes were most pronounced in 2022 — Other Gross PP&E Adjustments climbed 17.31% — and 2025, when it fell 0.9%.
• Alnylam Pharmaceuticals' Other Gross PP&E Adjustments stood at $481.8 million in 2022, then increased by 14.03% to $549.4 million in 2023, then advanced by 5.93% to $582.0 million in 2024, then rose by 10.13% to $640.9 million in 2025, then sank by 129.54% to -$189.3 million in 2026.
• Business Quant data shows ALNY's Other Gross PP&E Adjustments at -$189.3 million in Q1 2026, $640.9 million in Q4 2025, and -$191.4 million in Q3 2025.